Ajanta Pharma Limited CC-Sep23.pdf · 2023-10-31
My first question is on our India operations. So , in the past few years, most of our growth premium over I PM has come due to higher volumes in our India Branded business. Can you give a bit of color around this -- have we expanded our distribution network or are we going into smaller cities, so some color of why we are able to grow higher on volumes in India?
My next question is about our trade generics business in India. I think in the past calls, you guys had guided for 10%, 12% growth, but we continue to see very high growth of 15%, 20% in this division. This is not something I'm complaining about, but we also see a lot of other companies entering into this segment.